Este protocolo cubre la sarcoidosis cutánea que se presenta específicamente como lupus pernio — lesiones potencialmente desfigurantes que ocurren en el rostro, particularmente en la nariz o alrededor de ella, alrededor de los ojos o alrededor de la boca.
El régimen basado en evidencia para el lupus pernio implica la terapia anti-TNF. Dado el perfil de toxicidad de esta clase, la relación riesgo-beneficio debe evaluarse cuidadosamente para esta afección cutánea crónica. Los agentes específicos, las combinaciones y la secuenciación se detallan en el protocolo completo.
Other specific skin lesions include skin nodules that develop on old scars and tattoos; lesions that look like ulcers; lesions that may be mistaken for psoriasis; and lupus pernio, potentially disfiguring lesions that occur on the face, particularly on or around the nose, around the eyes or mouth.
For lupus pernio, a large retrospective study reported that anti-TNF therapy was significantly better than cytotoxic or antimalarial therapy, and it could be considered as second-line therapy for this particular form of skin sarcoidosis.
However, anti-TNF therapy is associated with more toxicity and the risk/benefit ratio must be considered in treating this chronic cutaneous condition.
View source ↗